tiprankstipranks
Precision BioSciences downgraded to Market Perform at BMO Capital
The Fly

Precision BioSciences downgraded to Market Perform at BMO Capital

BMO Capital analyst Kostas Biliouris downgraded Precision BioSciences to Market Perform from Outperform with a price target of $4, down from $7. The firm feels the company’s decision to deprioritize its in vivo pipeline while focusing on the development of ex vivo programs transitions the stock into a "show me" story, as the firm’s/investor conviction around the ex vivo platform "remains low until we see promising late-stage data."

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on DTIL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles